Maryland PDAB Gives Thumbs Up To Cost Reviews For Six Drugs

By Luke Zarzecki / May 20, 2024 at 6:05 PM

Maryland’s prescription drug affordability board (PDAB) voted Monday (May 20) to move forward with cost review studies for six drugs, including the blockbuster drug for diabetes and obesity Ozempic.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.